Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest

• मुख्य लेखकों: Alexander Egeberg (लेखक), Denis Jullien (लेखक), Kristian Gaarn Du Jardin (लेखक), Diamant Thaçi (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Background Five-year tildrakizumab safety data have been reported as exposure-adjusted incidence rates (EAIRs) of patients with events per 100 patient-years (PYs) of exposure. Objectives To present 5-year safety data from reSURFACE 1/2 phase 3 trials as EAIRs of events per 100 PYs of exposure, and t...